SunTrust Banks Analysts Give Celgene (CELG) a $127.00 Price Target

Celgene (NASDAQ:CELG) received a $127.00 target price from analysts at SunTrust Banks in a research report issued to clients and investors on Monday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. SunTrust Banks’ target price points to a potential upside of 19.44% from the stock’s current price.

A number of other brokerages have also recently issued reports on CELG. Leerink Swann reaffirmed a “buy” rating and set a $120.00 price objective on shares of Celgene in a research note on Friday. Credit Suisse Group set a $123.00 price objective on Celgene and gave the company a “buy” rating in a research note on Friday. Oppenheimer set a $166.00 price objective on Celgene and gave the company a “buy” rating in a research note on Friday. Cantor Fitzgerald reissued a “buy” rating and issued a $162.00 target price on shares of Celgene in a research note on Tuesday, September 26th. Finally, BMO Capital Markets reissued a “buy” rating and issued a $147.00 target price on shares of Celgene in a research note on Friday. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating, twenty-one have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $134.92.

Shares of Celgene (NASDAQ CELG) traded down $1.55 during trading hours on Monday, hitting $106.33. The stock had a trading volume of 9,611,900 shares, compared to its average volume of 4,833,915. The firm has a market cap of $83,720.00, a P/E ratio of 25.08, a price-to-earnings-growth ratio of 0.82 and a beta of 1.77. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52. Celgene has a 12 month low of $94.55 and a 12 month high of $147.17.

Celgene (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping analysts’ consensus estimates of $1.87 by $0.04. The firm had revenue of $3.29 billion during the quarter, compared to analyst estimates of $3.42 billion. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The company’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period in the previous year, the company posted $1.58 EPS. research analysts predict that Celgene will post 6.68 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in CELG. Neuberger Berman Group LLC raised its position in shares of Celgene by 4.0% during the 1st quarter. Neuberger Berman Group LLC now owns 1,844,837 shares of the biopharmaceutical company’s stock valued at $229,553,000 after buying an additional 71,729 shares in the last quarter. Grisanti Capital Management LLC bought a new position in Celgene during the 2nd quarter valued at about $3,616,000. Lincoln Capital Corp grew its holdings in Celgene by 0.6% during the 2nd quarter. Lincoln Capital Corp now owns 30,580 shares of the biopharmaceutical company’s stock valued at $3,971,000 after purchasing an additional 185 shares during the last quarter. RiverPoint Capital Management LLC grew its holdings in Celgene by 3.1% during the 2nd quarter. RiverPoint Capital Management LLC now owns 121,654 shares of the biopharmaceutical company’s stock valued at $15,799,000 after purchasing an additional 3,680 shares during the last quarter. Finally, Iguana Healthcare Management LLC grew its holdings in Celgene by 12.5% during the 1st quarter. Iguana Healthcare Management LLC now owns 90,000 shares of the biopharmaceutical company’s stock valued at $11,199,000 after purchasing an additional 10,000 shares during the last quarter. Institutional investors own 79.74% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “SunTrust Banks Analysts Give Celgene (CELG) a $127.00 Price Target” was first posted by Week Herald and is the sole property of of Week Herald. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://weekherald.com/2017/12/26/suntrust-banks-analysts-give-celgene-celg-a-127-00-price-target.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

SunTrust Banks Analysts Give Celgene (CELG) a $127.00 Price Target

Celgene (NASDAQ:CELG) received a $127.00 target price from analysts at SunTrust Banks in a research report issued to clients and investors on Monday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. SunTrust Banks’ target price points to a potential upside of 19.44% from the stock’s current price.

A number of other brokerages have also recently issued reports on CELG. Leerink Swann reaffirmed a “buy” rating and set a $120.00 price objective on shares of Celgene in a research note on Friday. Credit Suisse Group set a $123.00 price objective on Celgene and gave the company a “buy” rating in a research note on Friday. Oppenheimer set a $166.00 price objective on Celgene and gave the company a “buy” rating in a research note on Friday. Cantor Fitzgerald reissued a “buy” rating and issued a $162.00 target price on shares of Celgene in a research note on Tuesday, September 26th. Finally, BMO Capital Markets reissued a “buy” rating and issued a $147.00 target price on shares of Celgene in a research note on Friday. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating, twenty-one have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $134.92.

Shares of Celgene (NASDAQ CELG) traded down $1.55 during trading hours on Monday, hitting $106.33. The stock had a trading volume of 9,611,900 shares, compared to its average volume of 4,833,915. The firm has a market cap of $83,720.00, a P/E ratio of 25.08, a price-to-earnings-growth ratio of 0.82 and a beta of 1.77. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52. Celgene has a 12 month low of $94.55 and a 12 month high of $147.17.

Celgene (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping analysts’ consensus estimates of $1.87 by $0.04. The firm had revenue of $3.29 billion during the quarter, compared to analyst estimates of $3.42 billion. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The company’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period in the previous year, the company posted $1.58 EPS. research analysts predict that Celgene will post 6.68 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in CELG. Neuberger Berman Group LLC raised its position in shares of Celgene by 4.0% during the 1st quarter. Neuberger Berman Group LLC now owns 1,844,837 shares of the biopharmaceutical company’s stock valued at $229,553,000 after buying an additional 71,729 shares in the last quarter. Grisanti Capital Management LLC bought a new position in Celgene during the 2nd quarter valued at about $3,616,000. Lincoln Capital Corp grew its holdings in Celgene by 0.6% during the 2nd quarter. Lincoln Capital Corp now owns 30,580 shares of the biopharmaceutical company’s stock valued at $3,971,000 after purchasing an additional 185 shares during the last quarter. RiverPoint Capital Management LLC grew its holdings in Celgene by 3.1% during the 2nd quarter. RiverPoint Capital Management LLC now owns 121,654 shares of the biopharmaceutical company’s stock valued at $15,799,000 after purchasing an additional 3,680 shares during the last quarter. Finally, Iguana Healthcare Management LLC grew its holdings in Celgene by 12.5% during the 1st quarter. Iguana Healthcare Management LLC now owns 90,000 shares of the biopharmaceutical company’s stock valued at $11,199,000 after purchasing an additional 10,000 shares during the last quarter. Institutional investors own 79.74% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “SunTrust Banks Analysts Give Celgene (CELG) a $127.00 Price Target” was first posted by Week Herald and is the sole property of of Week Herald. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://weekherald.com/2017/12/26/suntrust-banks-analysts-give-celgene-celg-a-127-00-price-target.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply